Coronavirus drug in 6 months after producing API

News: Mumbai-based drug major Cipla, credited with several innovations especially in respiratory and flu therapy, could well become one of the first domestic companies to roll out new drugs for the coronavirus. The company is both fast-tracking development of these drugs with government laboratories, and repurposing its wide portfolio of respiratory, asthma, anti-virals and HIV drugs to meet challenges arising from Covid-19 in India.


Every year, through our #Breathefree initiative we reach out to over 2mn asthmatic patients, helping them to live a #BerokZindagi. We will continue our relentless pursuit until India breathes free.

#Asthma is a condition that needs to be managed properly with the help of an #inhaler. Watch as Radhika Apte, Chef Vikas Khanna, Parupalli Kashyap and Srishti tell you exactly why asthma ke liye #InhalersHainSahi.

How Cipla Is Embedding Digital Into Its Business Planning And Execution

Cipla is the third largest pharma company in India, an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai. The company is primarily into developing medicines to treat respiratory disorders, cardiovascular diseases, arthritis, diabetes, weight disorders, depression and other medical conditions.

Cipla’s Proventil Generic Gnaws At US Market

Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable’.

“Our belief is that there's a large share of this market that still writes albuterol generically. We do believe that albuterol as a category and not specifically as brand substitution is a thesis at play,” CEO Vohra said.

Source: Scrip, Anju Ghangurde

How Cipla Is Aligning Manufacturing Amid The Pandemic

The CFO also set out the overarching context, explaining that while media reports may be centered around repurposed COVID-19 treatments, the firm has seen robust demand across its core therapies. Cipla has been accelerating growth in the chronic segment in India, is “deeply entrenched” in CNS in South Africa and also continues to build on its respiratory hold in many markets including India, Europe, US and emerging markets.

“Supply chain, quality and manufacturing have come together. We have integrated business planning…this is one of the most advanced cloud-based business planning platforms and we are early adopters; this will drive significant efficiencies, improve our service levels phenomenally. And its end-to-end planning,” Upadhye explained

Source: Scrip, Anju Ghangurde